Clinical Outcomes with Direct Oral Anticoagulants Compared to Low Molecular Weight Heparins in the Treatment of Cancer-Associated Venous Thromboembolism

Conclusions: Bleeding events of patients treated with enoxaparin was comparable to rivaroxaban for both major and CRNM bleeding events in this carefully selected real-world population. Patients receiving rivaroxaban reported a statistically insignificant but lower rate of recurrent VTE compared to those receiving enoxaparin. These findings support a recent change in ISTH guidance recommending rivaroxaban or edoxaban as initial treatment of cancer-associated VTE in selected patients.DisclosuresKhorana: Sanofi: Consultancy; Bayer: Consultancy; Janssen: Consultancy; Pfizer: Consultancy.

Source: Blood - November 21, 2018 Category: Hematology Authors: Park, D. Y., Poudel, S. K., Jia, X., Wilks, M. L., Pinkava, V., O'Brien, M., Tripp, B., Song, J.-M., McCrae, K. R., Angelini, D. E., Khorana, A. A. Tags: 332. Antithrombotic Therapy: Poster I Source Type: research